1. Home
  2. JCE vs RCKT Comparison

JCE vs RCKT Comparison

Compare JCE & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JCE

Nuveen Core Equity Alpha Fund of Beneficial Interest

SELL

Current Price

$15.90

Market Cap

288.2M

Sector

Finance

ML Signal

SELL

Logo Rocket Pharmaceuticals Inc.

RCKT

Rocket Pharmaceuticals Inc.

SELL

Current Price

$2.04

Market Cap

277.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
JCE
RCKT
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
288.2M
277.7M
IPO Year
2007
2014

Fundamental Metrics

Financial Performance
Metric
JCE
RCKT
Price
$15.90
$2.04
Analyst Decision
Buy
Analyst Count
0
14
Target Price
N/A
★ $8.31
AVG Volume (30 Days)
27.5K
★ 1.6M
Earning Date
01-01-0001
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 26.37
EPS
N/A
★ 0.23
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,494.26
P/E Ratio
★ N/A
$9.20
Revenue Growth
N/A
N/A
52 Week Low
$13.99
$2.03
52 Week High
$17.45
$5.45

Technical Indicators

Market Signals
Indicator
JCE
RCKT
Relative Strength Index (RSI) 32.29 35.74
Support Level $15.59 N/A
Resistance Level $16.01 $2.73
Average True Range (ATR) 0.34 0.18
MACD -0.07 -0.02
Stochastic Oscillator 0.00 13.49

Price Performance

Historical Comparison
JCE
RCKT

About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest

Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the S&P 500 Index. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Share on Social Networks: